Quantcast
Home > Quotes > XBIO

Xenetic Biosciences, Inc. Common Stock (XBIO) Quote & Summary Data

XBIO 
$2.06
*  
0.07
3.29%
Get XBIO Alerts
*Delayed - data as of Feb. 15, 2019  -  Find a broker to begin trading XBIO now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
Today's High / Low
$ 2.169 / $ 2.05
Share Volume
17,641
50 Day Avg. Daily Volume
37,593
Previous Close
$ 2.13
52 Week High / Low
$ 8.95 / $ 1.3691
Market Cap
19,372,011
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
-4.84

Intraday Chart

Shares Traded

Share Volume:
17,641
50 Day Avg. Daily Volume:
37,593

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
Earnings Per Share (EPS):
$ -0.19

Trading Range

The current last sale of $2.06 is 50.46% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.169 $ 8.95
 Low: $ 2.05 $ 1.3691

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel oncology therapeutics. Our lead investigational product candidate is oncology therapeutic XBIO-101 (`sodium cridanimod') for the treatment of progestin - resistant endometrial cancer. We have exclusive rights to develop and commercialize XBIO-101 worldwide, except for specified countries in the Commonwealth of Independent States ("CIS"), including Russia. XBIO-101 has been granted orphan drug designation by the U.S. Food and Drug Administration ("FDA") for the potential treatment of progesterone receptor negative ("PrR-") endometrial cancer in conjunction with progesterone therapy. We are currently conducting a Phase 2 trial for XBIO-101, with the first patient dosed in October 2017, and expect to generate preliminary data from this trial before the end of 2018.  ... More ...  

Nasdaq Official Price

Open Price:
$ 2.19
Open Date:
Feb. 15, 2019
Close Price:
$ 2.06
Close Date:
Feb. 15, 2019

Research Brokers before you trade

Want to trade FX?

Analyst Info